The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
 
Kentaro Ito
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer
Research Funding - Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Kyorin (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Gilead Sciences; HUYA Bioscience International; Sysmex
Research Funding - Chugai/Roche (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satomi Watanabe
No Relationships to Disclose
 
Yoshihiro Hattori
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - MSD (Inst); Ono Pharmaceutical (Inst)
 
Kazumi Nishino
Honoraria - Chugai Pharma
 
Haruki Kobayashi
No Relationships to Disclose
 
Yuko Oya
No Relationships to Disclose
 
Toshihide Yokoyama
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takashi Seto
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Loxo (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Ono Pharmaceutical
 
Tomoya Fukui
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst)
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; MSD
Speakers' Bureau - AstraZeneca
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Katsuya Hirano
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Takashi Yokoi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
 
Haruko Daga
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Pfizer (Inst)
 
Shinya Sakata
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; CareNet; Chugai Pharma; Clinical Trial Co; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Merck Sharp & Dohme; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Reno Medical; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Speakers' Bureau - Astellas Pharma; Ono Pharmaceutical; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); Gritstone Bio (Inst); ICON Clinical Research (Inst); inVentiv Health (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Linical (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Quintiles Inc. (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Nippon Boehringer Ingelheim (Inst)